Medecamycin A1

Medecamycin A1 Uses, Dosage, Side Effects, Food Interaction and all others data.

Medecamycin A1 is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.

Reports have indicated that midecamycin is active against both erythromycin-susceptible and efflux-mediated erythromycin-resistant strains. The diacetate form of this product reduces gastrointestinal side effects and improves its pharmacokinetic profile. Studies have proved that midecamycin is highly active against Gram-positive organisms. The activity of midecamycin in the form of acetate salt presents a better activity, which seems to be potentiated at pH 7-8, as well as a longer half-life.

Trade Name Medecamycin A1
Generic Midecamycin
Midecamycin Other Names Espinomycin A, Medecamycin A1, Medemycin A1, Midecamycin, Midecamycin A1, Momicine, Mydecamycin A1, Platenomycin B1, Rubimycin, Turimycin P3
Type
Formula C41H67NO15
Weight Average: 813.979
Monoisotopic: 813.451070461
Protein binding

Midecamycin does not bind to plasma proteins in a significant proportion and thus, the bound form can account for about 15% of the administered dose. The acetate form of midecamycin presents a larger protein binding.

Groups Experimental
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Medecamycin A1
Medecamycin A1

Uses

Medecamycin A1 is a macrolide antibiotic used to treat a variety of infections caused by susceptible bacteria.

Medecamycin A1 was used for the treatment of infections in the oral cavity, upper and lower respiratory tracts and skin and soft tissue infections. The alone use of midecamycin was mainly used in Europe or Japan.

Medecamycin A1 is also used to associated treatment for these conditions: Abscess bacterial, Bacterial Pneumonia, Bronchitis bacterial, Laryngitis bacterial, Otitis Media (OM), Pharyngitis bacterial, Tonsillitis bacterial

How Medecamycin A1 works

Medecamycin A1, as part of the macrolides, act by inhibiting bacterial protein synthesis. More specifically, midecamycin inhibits bacterial growth by targetting the 50S ribosomal subunit preventing peptide bond formation and translocation during protein synthesis. The presence of mutations in the 50S RNA can prevent midecamycin binding. Medecamycin A1 is a broad spectrum antibiotic and thus, it can interact with different bacteria.

Volume of Distribution

The reported apparent volume of distribution of midecamycin is 7.7 L/kg.

Elimination Route

Medecamycin A1 is rapidly and almost completely absorbed when orally administered. It is mainly absorbed in the alkaline intestinal environment. This rapid absorption is due to its liposoluble property which allows for good penetration in the tissues, especially bronchial secretion, prostatic tissue, middle ear exudates and bone tissue. The tissue/serum ratio concentration is greater than 1 which indicates that this product does not stay long in the plasma. After oral administration of 600 mg of midecamycin, the peak serum concentration is 0.8 mg/L and it is attained 1 hour after oral administration. This concentration dereased significantly after 4-6 hours.

Half Life

The half-life of midecamycin is longer than the first macrolide antibiotics. after intravenous administration, the half-life reported is of 54 minutes.

Clearance

Medecamycin A1 presentas a low renal clearance value.

Elimination Route

The major route of elimination of midecamycin is is the liver, followed by a low significance of renal elimination. Urinary concentrations accounts for about 3.3% of the administered dose after 6 hours.

Innovators Monograph

You find simplified version here Medecamycin A1

*** Taking medicines without doctor's advice can cause long-term problems.
Share